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MepyramineDifferent brain areas seem to be involved in the cardiovascular responses to stress. The medial amygdala (MeA)
has been shown to participate in cardiovascular control, and acute stress activates the MeA to a greater extent
than any of the other amygdaloid structures. It has been demonstrated that the brain histaminergic system
may be involved in behavioral, autonomic and neuroendocrine responses to stressful situations. The aim of the
present study was to investigate the role of the histaminergic receptors H1 and H2 in cardiovascular responses
to acute restraint stress.Wistar rats (280–320 g) received bilateral injections of cimetidine,mepyramine or saline
into theMeA and were submitted to 45min of restraint stress. Mepyraminemicroinjections at doses of 200, 100
and 50 nmol promoted a dose-dependent blockade of the hypertensive response induced by the restraint stress.
Cimetidine (200 and 100 nmol) promoted a partial blockade of the hypertensive response to stress only at the
highest dose administered. Neither drugs altered the typical stress-evoked tachycardiac responses. Furthermore,
mepyramine and cimetidine were unable tomodify themean arterial pressure or heart rate of freelymoving rats
under basal conditions (non-stressed rats). The data suggest that in the MeA the histaminergic H1 receptors
appear to be more important than H2 receptors in the hypertensive response to stress. Furthermore, there
appears to be no histaminergic tonus in the MeA controlling blood pressure during non-stress conditions.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Stress may be deﬁned as a state of homeostatic imbalance that
activates a cohort of behavioral, neuroendocrine and autonomic re-
sponses in order to restore the physiological balance of the organism.
Chrousos proposed that responses to stressors could result in the re-
establishment of basal homeostasis (eustasis) or in an inadequate re-
turn of homeostasis to basal level (allostasis) or in an enhanced homeo-
static capacity (hyperstasis) [1]. Allostasis may be an insufﬁcient or anThe Brazilian Research Council
Bahia, Instituto de Ciências da
el Calmon, s/n, Vale do Canela,excessive adaptive response to stress and is more harmful to the organ-
ism, resulting in pathological conditions.
Withmodern day lifestyles, stress contributes to bothmorbidity and
mortality from chronic diseases [1]. Acute stress has been shown to ac-
count for a 1.38-fold greater risk of acutemyocardial infarction and con-
stitutes an important risk factor for hypertension [2]. According to the
Global Brief onHypertension published in 2013 by theWorldHealthOr-
ganization, approximately 17 million deaths occur annually worldwide
as a result of cardiovascular disease. In addition, according to that docu-
ment, hypertension is responsible for at least 45% of deaths due to heart
disease and 51% of deaths due to stroke [3].
Brain histamine is involved in arousal, the sleep–wake cycle, appe-
tite control, anxiety and memory [4–8]. Furthermore, histamine has
been implicated in some pathological conditions such as schizophrenia,
Alzheimer's disease, Parkinson's disease and Tourette's syndrome, and
in addictive behavior [9–11]. Histamine seems to play a protective role
against noxious stimuli such as pain, convulsion and stress. The release
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responses, allowing the individual to cope with stress situations [5,8,
12]. Indeed, several types of stressors are able to activate histaminergic
neurons of the tuberomamillary nucleus (TMN) [4,13] Furthermore,
acute and chronic stress increases histamine turnover in different
brain areas such as the hypothalamus, cortex, nucleus accumbens, stri-
atum and midbrain [14–17]. Histamine has been shown to mediate the
release of neurotransmitters and stress-related hormones such as sero-
tonin, noradrenaline, corticotrophin-releasing hormone, vasopressin
and β-endorphin [5,18,19]. Based on these data, it has been suggested
that histamine release could be used as an indicator of stress [4,5]. How-
ever, the nature of the participation of histamine in the responses to
stress is not completely understood.
Different brain areas seem to be involved in the cardiovascular re-
sponses to stress, including the lateral and medial septal area, supraop-
tic nucleus, paraventricular nucleus (PVN), dorsomedial hypothalamus
(DMH), the bed nucleus of the stria terminalis, amygdaloid nuclei,
periaqueductal gray, locus ceruleus, the nucleus tractus solitarius
(NTS) and the rostral ventrolateral medulla (RVLM) [10,20,21]. It is
noteworthy that, of these areas, the amygdaloid complex is fundamen-
tal in processing emotions and is crucial in integrating the autonomic,
neuroendocrine and behavioral responses to stressful conditions [22].
Both the central amygdala (CeA) and the medial amygdala (MeA)
have been shown to participate in cardiovascular control [23,24]. How-
ever, acute emotional stress activates the MeA to a greater extent than
any of the other amygdaloid structures [25–27]. Lesions of the MeA
have been shown to decrease cardiovascular response to restraint stress
and attenuate the development of hypertension in spontaneously hy-
pertensive rats [28,29].
The MeA has been shown to receive histaminergic projections from
the TMN [30,31]. Furthermore, microinjections of histamine in theMeA
modulate the baroreﬂex, and analysis of the heart rate variability indi-
cates a decrease in the vagal component of the baroreﬂex and an in-
crease in the sympathetic/parasympathetic balance under basal
conditions [32]. These data support the idea that histaminergic activity
in the MeA may modulate cardiovascular responses. Although there
are studies showing the participation of central histaminergic pathways
in the control of blood pressure under a cardiovascular challenge such
as hemorrhagic shock [33], it is not known whether histaminergic sys-
tems directly regulate blood pressure under stress conditions. There-
fore, the aim of the present study was to investigate the role of H1 and
H2 receptors in the MeA in cardiovascular responses to stress. Since
the MeA is involved in the behavioral and cardiovascular responses to
stress and since the expression of histaminergic receptors in the MeA
is dense [4,5,30,34,35], our hypothesis is that histamine released in
theMeA during stressmay activate H1 and H2 receptors and this activa-
tionmay be important for the cardiovascular response to restraint stress
in rats.
2. Materials and methods
2.1. Animals
AdultmaleWistar rats (280–300 g)were kept under controlled light
(lights on from 6 AM to 7 PM) and temperature (22 ± 2 °C) conditions
with free access to tap water and laboratory chow (Nuvital Nutrientes
Ltda., Curitiba, Brazil). All experiments were conducted between 7 AM
and 11 AM. The experimental protocols were performed in accordance
with the regulations for the care of laboratory animals and were ap-
proved by the institution's Animal Ethics Committee (CEUA-ICS-UFBA
# 018/2011).
2.2. Surgical procedures
Cannulation of the MeA was performed under ketamine/xylazine
(80/11.5 mg/kg i.p.) anesthesia. Five days before the experimentalsessions, a stereotaxic apparatus (David Kopf Instruments, Tujunga,
CA) was used to implant a 15 mm, 22-gauge, stainless steel cannula.
The following coordinates were used: anteroposterior = 2.5 mm be-
hind the bregma; lateral = ± 3.4 mm; vertical 8.3 mm below the
skull [36]. The animals were placed in the stereotaxic apparatus with
their heads in the horizontal position. The cannulas were cemented to
the skull bone with dental acrylic and an obturator (25-gauge) was
placed to avoid obstruction. The day before the experimental sessions,
a catheter (PE50) ﬁlled with heparinized saline solution (1000 U/ml)
was inserted into the left carotid artery under ketamine/xylazine anes-
thesia, and exteriorized at the nape of the animal's neck to permit blood
pressure recording. After both surgeries, the animals were treated with
an antibiotic combination of penicillin and streptomycin (Pentabiótico,
Fort Dodge Ltda., Brazil; 0.2 ml/rat i.m.) and with the analgesic/anti-
inﬂammatory agent, ﬂunixin meglumine (2.5 mg/kg i.m.) and then
housed in individual cages.
2.3. Drugs and microinjections
The following drugs were used: mepyramine maleate (N-[(4-
methoxyphenyl)methyl]-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-
diamine) an H1 histaminergic receptor antagonist/inverse agonist, and
cimetidine, an H2 histaminergic receptor antagonist [37–39]. Bothwere
purchased from Sigma Co., St. Louis, MO, USA. All the drugs were dis-
solved in isotonic saline solution. The doses of mepyramine used here
were based on previous studies conducted by this same group and on
data published in the literature [40–44]. Central injections were given
using a Hamilton microsyringe connected through polyethylene tubing
to a 30-gauge injector that was 1 mm longer than the guide cannula. A
total volume of 200 nl was slowly injected (60 s) and the injector
remained in the guide cannula for an additional 60 s.
2.4. Blood pressure recording
At the beginning of the experiment, the arterial catheters were
gently connected, with the unrestrained animals in their home cages.
Arterial pressure was continuously monitored through the carotid
catheter connected to a blood pressure transducer (World Precision In-
struments) whose signal was ampliﬁed and digitally recorded by an
analog-to-digital interface (AqDados — application for data acquisition,
Lynx Tecnologia Eletrônica Ltda., São Paulo, Brazil, version 7.0) and re-
corded (1 kHz) on a microcomputer for later analysis. In all experimen-
tal sets, pulsatile blood pressure was recorded for 30 min prior to the
administration of any drug (baseline blood pressure), with the animals
undisturbed in their home cages in a quiet room, thus assuring the in-
vestigator that each animal had normal and stable blood pressure and
heart rate. Mean arterial pressure was calculated from the systolic and
diastolic pressure, while heart rate was determined from pulsatile
blood pressure using the AcqKnowledge software program, version
3.5.7, developed by Biopac Systems, Inc., California, USA. Mean arterial
pressure and heart rate values at the end of the stabilization period
(30 min) were considered reference values from which the data used
in the present study were calculated. Each data point on the graphs
represents the mean ± SEM of a group of animals' data and each indi-
vidual animal's data represents an average of 1-minute data taken
every 5 min of recording.
2.5. Restraint stress
Restraint stress was induced by placing the animals for 45 min in-
side plastic (PVC) tubes speciﬁcally designed to restrict their move-
ments without promoting any apparent signs of pain. The tubes were
provided with multiple holes to facilitate heat dissipation and an ante-
rior and posterior opening for the nose and tail. The arterial catheter ex-
teriorized in the animal's neck was connected to the blood pressure
transducer through a special aperture located in the upper part of the
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arterial pressure and heart rate in rats receiving injections of saline
solution into the MeA compared to non-stressed animals.
2.6. Experimental design
The participation of H1 and H2 histaminergic receptors in cardiovas-
cular responses induced by restraint stress was investigated in different
groups of animals receiving bilateral injections of mepyramine (50, 100
and 200 nmol), cimetidine (100 and 200 nmol) or saline (control) into
the MeA. The histaminergic antagonists were administered 10 min
prior to initiating the restraint stress (time 0), with the animals in
their home cages. Pulsatile blood pressurewas recorded for an addition-
al 15 min following restraint stress (recovery period), also with the an-
imals in their home cages. To evaluatewhether H1 andH2 histaminergic
receptors in the MeA could exert any tonic regulatory control on the
blood pressure and heart rate of non-stressed rats, separate groups of
animals received bilateral injections of saline solution (controls),
200 nmol of mepyramine or cimetidine into theMeA and their pulsatile
blood pressure was recorded for 70 min.
2.7. Histological procedures
At the end of the experiments, the animals were anesthetized with
sodium thiopental (40 mg/kg i.p.) and submitted to transcardiac perfu-
sion with isotonic saline solution followed by 10% formalin. In addition,
they received bilateral injections of Evans Blue dye into the MeA at a
volume of 200 nl per side. The brains were then removed and ﬁxed in
10% formalin. The specimens were frozen and cut into 40 μm sections.
To conﬁrm the injection sites in relation to the MeA, the slices were
stainedwith cresyl violet and analyzed by lightmicroscopy. Fig. 1A con-
sists of a photomicrograph showing the typical appearance of the brain
parenchyma surrounding the MeA after cannulation and the site of the
injection of Evans Blue dye into the MeA. A diagram is also shown
[adapted from 36] indicating the site of injections into the MeA and
the off-target sites (Fig. 1B). In the present study, drug diffusion was
not directly evaluated. We cannot exclude the possibility that the
drugs may have diffused to the vicinity of the MeA. However, the data
from the animals whose cannulas were located outside the MeA or inTable 1
Comparison of cardiovascular parameters between stressed and non-stressed rats that re-
ceived microinjections of saline 0.9% in the MeA during the experimental period.
Time
(min)
Non-stressed Rats Stressed Rats
ΔMAP±SEM 
(mmHg)
ΔHR±SEM 
(bpm)
ΔMAP±SEM 
(mmHg)
ΔHR±SEM 
(bpm)
-10 0.6 ± 1.2 8.2 ± 8.2 1.0 ± 1.8 2.6 ± 8.0
0 3.1 ± 0.9 -0.8 ± 8.6 3.6 ± 1.5 9.3 ± 8.3
St
re
ss
 P
er
io
d 10 2.2 ± 1.6 11.6 ± 14.2 24.6 ± 1.3* 137.8 ± 17.7*
20 2.2 ± 0.8 12.8 ± 12.1 24.4 ± 0.8* 147.9 ± 14.4*
30 2.4 ± 1.2 9.3 ± 5.7 24.4 ± 0.7* 135.4 ± 11.3*
40 1.0 ± 1.5 5.6 ± 8.7 24.9 ± 1.9* 118.2 ± 11.2*
50 4.4 ± 1.4 2.6 ± 8.3 8.3 ± 2.2 99.9 ± 17.6*
Basal values for MAPwere 103.5 ± 4.6 mmHg in non-stressed group (n= 8) and 96.7 ±
2.6 mm Hg in stressed group (n = 9). Basal values for HR were 358.1 ± 16.4 bpm in the
non-stressed group and 322.0 ± 8.6 in the stressed group. Saline was injected bilaterally
into the MeA at−10 min; the restraint stress period started at time 0 and ended at 45
min. *The mixed-model analysis of variance (ANOVA) followed by the Bonferroni post-
hoc test showed signiﬁcant differences when compared to the group of non-stressed
rats p b 0.05. MeA=medial amygdala; MAP =mean arterial pressure; HR = heart rate.its vicinity show that the histaminergic antagonists exerted no statisti-
cally signiﬁcant effect on the hypertensive response to stress. The data
from the animals in which the injections were off target are summa-
rized in Table 2. Only the data from the animals in which the injections
were located in the MeA were analyzed and taken into consideration in
the analysis of the effects of the pharmacological agents on cardiovascu-
lar responses.
2.8. Statistical analysis
The data are presented as means ± standard error of the mean
(SEM). Statistical analyses were performed using the GraphPad Prism
software (GPAD, version 6.03, San Diego, USA). Mean arterial pressure
and heart rate were analyzed separately using a mixed-model analysis
of variance (ANOVA) with time as the within-subjects repeated mea-
sure and drug treatment as the between-subjects variables (not repeat-
ed). The Bonferroni post-hoc test was used to compare the effects of the
drugs during each measurement period. Differences between the
groups were considered statistically signiﬁcant at p b 0.05. The compar-
ison of the inhibitory effect of the blockade of H1 andH2 receptors at the
MeA on the hypertensive response to restraint stress was analyzed in
the middle of the period of restraint stress (25 min) using one-way
ANOVA followed by the Bonferroni post-hoc test. Differences between
the groups were considered statistically signiﬁcant at p b 0.05.
3. Results
Restraint stress promotes a signiﬁcant increase in blood pressure
and heart rate in rats receiving bilateral injections of saline solution
into the MeA compared to non-stressed rats receiving the same treat-
ment (Table 1).
The blockade of H1 receptors in the MeA reduces the hypertensive
response to restraint stress in a dose-dependent way. As expected, an
increase in blood pressure occurred in the control group that oscillated
between 27 mm Hg and 22 mm Hg during the 45-minute period of re-
straint stress. In the group of animals receiving bilateral injections of
mepyramine at the doses of 100 and 200 nmol into theMeA, the hyper-
tensive response induced by the restraint stress was signiﬁcantly
inhibited. However, the inhibitory effect promoted by mepyramine at
the dose of 100 nmol was less pronounced (alternating at around 16
and 13 mm Hg) compared to the dose of 200 nmol (12 to 4 mm Hg).
The hypertensive response of the group treated with mepyramine at
the dose of 50 nmol was similar to that of the control group. Prior to
the initiation of restraint stress, the blood pressure of the animals in
the mepyramine-treated groups, at all the doses used, was similar to
that of the control group. During the recovery period following the
end of restraint stress, blood pressure was similar in all the groups
(Fig. 2A). The tachycardic response induced by restraint stress remained
unaltered by the blockade of H1 receptors at the MeA (Fig. 2B). The re-
sults of the mixed model ANOVA applied in this experimental set are
shown in Table 3.
The hypertensive response to restraint stress was partially inhibited
by the blockade of H2 receptors at the MeA. Blood pressure values dur-
ing restraint stress in the group receiving 200 nmol of cimetidine were
around 20 and 12 mm Hg, while blood pressure values in the control
group alternated around 27 and 23 mm Hg. In the group of animals
treated with 100 nmol of cimetidine, the hypertensive response was
similar to that of the control group (oscillating at around 24 and
20 mm Hg). The blockade of H2 receptors at the MeA did not alter
blood pressure prior to restraint stress. During the recovery period,
blood pressure was similar in all the groups (Fig. 3A). The blockade of
H2 receptors at the MeA did not change the tachycardic response in-
duced by restraint stress (Fig. 3B). The results of the mixed model
ANOVA applied in this experimental set are shown in Table 3.
The inhibitory effect of the blockade of H1 and H2 receptors at the
MeA on the hypertensive response induced by restraint stress was
Fig. 1. Panel A: Photomicrograph of a coronal section showing the typical position of the cannulaswithin theMeA. To conﬁrm the injection sites in relation to theMeA, brain slices (40 μm)
were stained with cresyl violet and analyzed by light microscopy. Only the data from the animals in which the cannulas were placed bilaterally within the MeAwere analyzed and taken
into consideration. Panel B: Diagrammatic representation (adapted from reference [22]: The Rat Brain Atlas of Paxinos and Watson, 1998) of the injection sites within (•) and outside
(x) theMeA. ACo= anterior cortical amygdaloid nucleus; BMA=basomedial amygdala, anterior part; LH= lateral hypothalamic area; MeA=medial amygdala nucleus;MGP=medial
globus pallidus.
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expected, there was a signiﬁcant increase in the blood pressure of
the saline-treated animals submitted to restraint stress compared
to the saline-treated non-stressed animals. At a dose of 100 nmol,
mepyramine signiﬁcantly attenuated the hypertensive response to re-
straint stress, while cimetidine given at the same dose failed to modify
stress-induced hypertension. At the dose of 200 nmol, both histaminer-
gic antagonists inhibited the hypertensive response to restraint stress.
However, blood pressure in the group treated with mepyramine was
signiﬁcantly lower (7.2 ± 2.1 mm Hg) compared to that of the
cimetidine-treated group (14.8 ± 1.4 mm Hg). Furthermore, bloodTable 2
Effect of bilateral injections of saline 0.9%, mepyramine (200 n
areas (MGP, BMA, ACo and LH) on MAP and HR values of restr
Time
(min)
Saline 0.9% Mepyra
ΔMAP±SEM
(mmHg)
ΔHR±SEM 
(bpm)
ΔMAP±SE
(mmHg)
-10 1.9±1.9 -0.6±3.7 0.7±1.4
0 4.6±3.4 31.6±11.7 5.8±6.4
St
re
ss
 P
er
io
d 10 26.0±2.1 145.9±18.9 25.5±2.1
20 23.1±1.5 152.2±13.0 20.9± 2.4
30 23.1±2.1 127.6±10.4 22.0± 2.4
40 24.5±3.0 125.5±15.7 22.2± 2.7
50 8.4±3.4 103.3±16.2 13.5± 2.2
Basal values forMAPwere 108.7± 2.0mmHg (saline group; n
105.5 ± 1.9 mm Hg (cimetidine group; n = 6). Basal values fo
bpm (mepyramine group) and 328.5 ± 5.5 bpm (cimetidine g
laterally into the MeA at−10 min; the restraint stress period
analysis of variance (ANOVA) followed by the Bonferroni post-h
at any parameter. MGP = medial globus pallidus; BMA = bas
amygdaloid nucleus; and LH= lateral hypothalamus; MAP=pressure in the mepyramine-treated rats was similar to that of the
saline-treated, non-stressed rats (Fig. 4).
The blockade of H1 and H2 receptors had no effect on the hyperten-
sive response or on the tachycardic response to restraint stress when
the histaminergic antagonists were injected into sites located outside
the MeA (Table 2).
Bilateral injections of cimetidine and mepyramine at the highest
dose used (200 nmol) into the MeA of non-stressed rats had no effect
on blood pressure or heart rate (Fig. 5A and B). The results of the
mixed model ANOVA applied in this experimental set are shown in
Table 3.mol) or cimetidine (200 nmol) into the MeA surrounding
aint stressed rats.
mine 200nmol Cimetidine 200nmol
M ΔHR±SEM 
(bpm)
ΔMAP±SEM 
(mmHg)
ΔHR±SEM 
(bpm)
4.0±6.9 3.4±1.7 1.9±12.7
23.1±11.5 3.2±2.4 34.0±20.5
168.1±13.7 19.3±1.6 158.9±7.8
137.3±25.6 18.2±1.4 138.7±11.7
138.6±20.0 17.8±2.3 139.1±12.2
141.0±16.0 20.9±2.3 133.9±10.9
94.8±23.5 8.7±3.4 94.5±14.9
=8), 107.3±4.5mmHg (mepyramine group; n=5) and
r HR were 340.1 ± 9.38 bpm (saline group), 344.2 ± 10.2
roup). Mepyramine, cimetidine or saline were injected bi-
started at time 0 and ended at 45 min. The mixed-model
oc test showed no signiﬁcant differences between groups
omedial amygdala, anterior part; ACo = anterior cortical
mean arterial pressure; HR = heart rate.
Fig. 2. Changes (Δ) inmean arterial pressure (MAP— panel A) and heart rate (HR— panel
B) in animals receiving MeA injections of mepyramine at different doses, or saline. Data
are presented as means ± SEM. The following groups are presented: saline (□; n = 7;
basal MAP = 99.4 ± 3.4 mm Hg; basal HR = 332.8 ± 8.5 bpm), mepyramine 50 nmol
(◆; n= 7; basal MAP=109.2± 1.9mmHg; basal HR=334.0± 11.3 bpm),mepyramine
100 nmol (▲; n = 8; basal MAP = 105.7 ± 1.2 mm Hg; basal HR = 337.6 ± 5.9 bpm),
mepyramine 200 nmol (●; n = 7; basal MAP = 110.6 ± 5.1 mm Hg; basal HR =
344.5 ± 9.2 bpm). The symbol * indicates statistically signiﬁcant differences (mixed
model design ANOVA followed by the Bonferroni post-hoc test) when drug-treated
groups are compared to saline-treated controls. The symbol # indicates statistically signif-
icant differences when the groups receivingmepyramine at the doses of 50 and 100 nmol
were compared to the animals receiving mepyramine at the dose of 200 nmol.
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The present study investigated the role of H1 and H2 receptors in the
MeA in relation to cardiovascular responses to stress. The brain hista-
minergic pathways originate in the TMN, which sends ﬁber projections
in a diffuse manner to prosencephalic and rhombencephalic structures
such as the septal area, preoptic area, suprachiasmatic nucleus, supraop-
tic nucleus, paraventricular nucleus, anterior hypothalamic area, the
bed nucleus of the stria terminalis, the amygdaloid complex, nucleus
of the solitary tract and the parabrachial nucleus [31,45–47]. Recent
studies using knockout mice and positron emission tomography in
humans have clariﬁed some of the functions of the brain histaminergic
system [8]. The brain histaminergic system appears to be involved
in different regulatory functions such as the sleep–wake cycle,arousal, anxiety, the release of hormones from the pituitary gland,
antinociception, sodium and water balance and feeding behavior [5].
In addition, stimulation of the brain histaminergic system may modu-
late cardiovascular function [48–50].
Four classes of histamine receptors have been identiﬁed: H1, H2, H3
and H4. These are widely and diffusely distributed throughout the
brain, with high to moderate expression in the hippocampus, hypotha-
lamic nuclei, and amygdaloid complex [4,5,34,35]. H1 receptors are
coupled to inositol phospholipid hydrolysis via Gq/11 and H2 receptors
are positively coupled to adenylyl cyclase via Gs protein, mediating an
increase in cAMP. On the other hand, H3 and H4 are both coupled to Gi
protein, mediating a decrease in cAMP [4,5,34,51]. In the amygdaloid
complex, the MeA receives the densest afferent projections from the
TMN, with a high density of H1 receptors and a moderate density of
H2 receptors [4,5,30,34,35]. This characteristic suggests a functional
role of histamine and its receptors in this area.
Different research groups have been investigating the brain neuro-
transmitters that participate in the control of autonomic nervous sys-
tem activity and cardiovascular responses to stress. It has been shown
that serotonin, noradrenaline, dopamine, vasopressin and angiotensin
may be involved in these control mechanisms [1,20,52–56]. Among
the brain areas involved in cardiovascular control during stress, the
amygdaloid complex, particularly theMeA area, is important in regulat-
ing the cardiovascular responses associated with emotion [28,57–59].
Although the MeA receives histaminergic projections from the TMN,
has H1 andH2 receptors and is involved in the brain circuitry controlling
emotional responses [60], the role of histamine in the MeA on the con-
trol of cardiovascular responses to stress is unclear.
In the present study, the blockade of H1 and H2 receptors in theMeA
reduced the hypertensive response to restraint stress in rats, although
the inhibitory effect of the blockade of H1 receptors was more intense
than the blockade of H2 receptors. The role of the brain histaminergic
system in the response to stress has been described through the use of
different research protocols. Several types of stressors increase the ac-
tivity of histaminergic neurons in the TMN [4,13,48] and histamine
turnover increases in different brain areas in both acute and chronic
stress [17]. Indeed, there is depletion of histamine in the hypothalamus,
thalamus, midbrain and cerebral cortex after 1 or 2 hours' exposure to
restraint stress, extreme cold or the combination of both, indicating
that these stressorsmay increase the use of histamine [12]. Our hypoth-
esis is that histamine release in the MeA during stress may activate H1
andH2 receptors and this activationmay be important for the hyperten-
sive response to restraint stress in rats. Since the density of H1 receptors
is higher than that of the H2 receptors in the MeA, this variation in
receptor density may be partially responsible for the difference in the
inhibitory response induced by the blockade of each of these histamin-
ergic receptors in the MeA.
It has been demonstrated that different stressor stimuli activate
selective neuronal circuitries, allowing the different types of stress (psy-
chological and physical) to be categorized, and triggering the appropri-
ate physiological response [61]. TheMeA appears to constitute a crucial
part of the brain circuitry involved in the adaptive responses to emo-
tional stress, while the CeA participates in the responses to physical
stress [62]. In rats submitted to restraint stress, a greater number of
Fos positive cells are present in the MeA than in the CeA and there is
an increase in Fos expression in the paraventricular and supraoptic nu-
cleus [21,26,28,60]. The MeA appears to be more important than the
CeA in generating the neuroendocrine response to an unconditioned
emotional stressor such as restraint [60,62] and activation of the
hypothalamic-pituitary axis during stressmay depend on the functional
integrity of the MeA [60,63]. Restraint stress also activates catechol-
amine cell groups in the RVLM and this activation may be dependent
on inputs from the MeA to the PVN that, in turn, sends efferent projec-
tions directly to the RVLM [64].
In non-stressed animals, the histaminergic stimulation of the brain
results in an increase in blood pressure and in sympathetic activity in
Table 3
Statistical summary of mixed model ANOVA results of all experimental protocols.
Experimental protocol Parameter Interaction
(time × drug)
Time Drug
F(DFn,DFd) p-Value F(DFn,DFd) p-Value F(DFn,DFd) p-Value
Experiment 1
Mepyramine + restraint stress
MAP (mm Hg) F(48,400) = 4.61 b0.0001 F(16,400) = 75.98 b0.0001 F(3,25) = 13.17 b0.0001
HR (bpm) F(48,400) = 0.80 =0.8313 F(16,400) = 76.49 b0.0001 F(3,25) = 0.22 =0.8809
Experiment 2
Cimetidine + restraint stress
MAP (mm Hg) F(32,240) = 3.05 b0.0001 F(16,240) = 86.26 b0.0001 F(2,15) = 17.07 =0.0001
HR (bpm) F(32,240) = 0.77 =0.8108 F(16,240) = 63.00 b0.0001 F(2,15) = 0.32 =0.7285
Experiment 3
Mepyramine or cimetidine +
non-stress
MAP (mm Hg) F(32,288) = 1.10 =0.3300 F(16,288) = 1.39 =0.1468 F(2,18) = 3.49 =0.0523
HR (bpm) F(32,288) = 1.12 =0.3037 F(16,288) = 1.06 =0.3968 F(2,28) = 2.96 =0.0773
The mean arterial pressure and heart rate values were analyzed separately using a mixed-model analysis of variance (ANOVA) with one repeated measure factor (sixteen levels of time)
and one group factor (drugs) not repeated. The post-hoc Bonferroni test was used to compare the effect of the drugs at eachmeasurement time period, as shown in Figs. 2, 3 and 4. HR=
heart rate; MAP =mean arterial pressure.
Fig. 3. Changes (Δ) inmean arterial pressure (MAP— panel A) and heart rate (HR— panel
B) in animals receiving MeA injections of cimetidine at different doses, or saline. Data are
presented as means ± SEM. The following groups are presented: saline (□; n = 7; basal
MAP = 102.2 ± 4.4 mm Hg; basal HR = 347.6 ± 19.3 bpm), cimetidine 100 nmol (▲;
n = 5; basal MAP = 106.9 ± 1.8 mm Hg; basal HR = 355.1 ± 17.7 bpm), cimetidine
200 nmol (●; n = 6; basal MAP = 109.7 ± 4.6 mm Hg; basal HR = 350.4 ± 10.3 bpm).
The symbol * indicates statistically signiﬁcant differences (mixed model design ANOVA
followed by the Bonferroni post-hoc test) when drug-treated groups are compared to sa-
line-treated controls. The symbol # indicates statistically signiﬁcant differences when the
group receiving cimetidine at the dose of 100nmolwas compared to the animals receiving
cimetidine at the dose of 200 nmol.
100 D.O. de Almeida et al. / Physiology & Behavior 144 (2015) 95–102rats [33,48–50]. The hypertensive effect of central injections of hista-
mine may be mediated by sympathetic activation [65] and the release
of vasopressin, catecholamines and angiotensin II [48,66,67]. On the
other hand, the results of the present study show that the blockade of
H1 and H2 receptors in the MeA did not alter blood pressure in rats
under non-stress conditions. This ﬁnding suggests that under non-
stress conditions there is no histaminergic tonus in theMeA controlling
blood pressure.
In addition to the hypertensive response induced by activation of the
central histaminergic receptors, both bradycardia and tachycardia have
been seen in non-stressed animals. Depending on the regions of the
brain intowhich the histamine injections are given and the state of con-
sciousness of the animal, the effects of histamine on heart rate may be
diverse [44,50]. Histamine injections into the PVN and anterior hypo-
thalamus promote a tachycardic effect. A similar effect is also observed
following the injection of H1 receptor agonists into the NTS [66,68]. On
the other hand, injections of histamine into the intracerebroventricular
system, RVLM and dorsal raphe nucleus induce a bradycardic effect [50,
69,70]. In the present study, the blockade of H1 and H2 receptors in the
MeA failed to alter heart rate, either in stressed or non-stressed
animals. Some studies have suggested that the cardiac and vasomotorFig. 4. Comparison of the effect of H1 and H2 receptor blockade in the MeA on the hyper-
tensive response 25min after the beginning of the restraint stress period. The doses of the
antagonists used in the comparison were 100 and 200 nmol, with 0 representing the sa-
line-treated control group. Data are presented as means ± SEM. The letter “a” indicates
statistically signiﬁcant differences when stressed groups are compared to non-stressed,
saline-treated animals. The letter “b” indicates statistically signiﬁcant differences when
stressed drug-treated groups are compared to stressed, saline-treated animals. The sym-
bol * indicates statistically signiﬁcant differences when the stressed cimetidine-treated
group is compared to the stressedmepyramine-treated group (one-way ANOVA followed
by the Bonferroni post-hoc test).
Fig. 5. Changes (Δ) in mean arterial pressure (MAP - panel A) and heart rate (HR - panel
B) in non-stressed rats receiving MeA injections of cimetidine and mepyramine at the
dose of 200 nmol or saline. Data are presented as means ± SEM. The following groups
are presented: saline (□; n = 6; basal MAP = 106.3 ± 2.6 mm Hg; basal HR =
347.8 ± 13.1 bpm), mepyramine (▲; n = 8; basal MAP = 113.7 ± 1.8 mm Hg; basal
HR = 360.9 ± 18.2 bpm), cimetidine (●; n = 7; basal MAP = 109.7 ± 3.7 mm Hg;
basal HR = 361.5 ± 13.8 bpm).
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have been demonstrated from the MeA to the DMH [72,73], which in
turn, maymodulate vascular tonus via RVLM interplay and may control
cardiac function through connections in the raphe/parapyramidal area
[71,74,75]. The data found in the present study suggest that the hista-
minergic H1 and H2 receptors in the MeA may activate the descending
pathway from the DMH controlling vascular tonus, but are possibly
not involved in the cardiac function pathway modulating heart rate.
Otherwise, connections from the MeA to the PVN, which sends direct
projections to the RVLM, may be responsible for the increase in blood
pressure during acute stress. Indeed, a moderate output from the MeA
to the DMH has been demonstrated; nevertheless, there are dense pro-
jections to the bed nucleus of the stria terminalis, which in sequence
send massive projections to the PVN [76–79]. The blockade of the H1
and H2 receptors at the MeA disrupts this circuitry, hampering the hy-
pertensive response to restraint stress but not the tachycardic response.
Further studies should be conducted to conﬁrm these hypotheses.
In summary, the most intriguing ﬁnding of this study is that the
blockade of histaminergic H1 and H2 receptors in the MeA impairs thehypertensive response to acute restraint stress without altering
tachycardic response. Regarding the types of histaminergic receptors
in theMeA, H1 receptors appear to bemore important thanH2 receptors
in the hypertensive response to stress. Furthermore, there appears to be
no histaminergic tonus in the MeA controlling blood pressure during
non-stress conditions. Further studies are necessary to demonstrate
the turnover of histamine in the MeA and the possible interaction of
brain histaminergic pathways with other brain neurotransmitters con-
trolling cardiovascular responses during stress.
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